INTERACTIONS BETWEEN ENDOTHELIAL SECRETAGOGUES

被引:15
作者
GRYGLEWSKI, RJ
机构
[1] Department of Pharmacology, Jagiellonian University Medical College, Cracow
关键词
PROSTACYCLIN; NITRIC OXIDE; NO DONORS; TISSUE PLASMINOGEN ACTIVATOR; STREPTOKINASE; ENDOTHELIUM; THROMBOLYSIS; THROMBOGENESIS; PLATELETS; FIBRINOLYSIS; INTERACTIONS;
D O I
10.3109/07853899509002595
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among endothelial secretogogues prostacyclin (PGI(2)), nitric oxide (NO) and tissue plasminogen activator (t-PA) play a crucial role in maintaining thromboresistance, tone and structure of the vascular wall. Most receptor agonists, such as B-2 kinin receptor agonists, or shear force produce a coupled release of all three secretogogues, and therefore interactions between them are to be expected. Essentially, PGI(2) is a platelet suppressant, NO a vasodilator and t-PA a fibrinolytic agent. These and other properties of endothelial secretogogues supplement each other in protecting the cardiovascular system from injuries. It is not surprising that disturbances of the secretory function of endothelial cells are associated with atherosclerosis, diabetes, thrombosis or hypertension. Traditionally, PGI(2), NO, t-PA or their substitutes are used individually for the treatment of peripheral arterial disease, angina pectoris or acute myocardial infarction. In light of recent findings, their joint administration can be advocated. For instance, NO donors will potentiate platelet-suppressant action of PGI(2) analogues, whereas exogenous PGI(2) or TXA(2) synthase inhibitors (i.e. following increase in endogenous PGI(2)) will abolish a paradox of prothrombotic action of t-PA or streptokinase. The replacement therapy with PGI(2), NO or t-PA should match as closely as possible the physiologically coupled release of these secretogogues.
引用
收藏
页码:421 / 427
页数:7
相关论文
共 80 条
[1]   PROSTAGLANDIN-I2 HALF-LIFE REGULATED BY HIGH-DENSITY-LIPOPROTEIN IS DECREASED IN ACUTE MYOCARDIAL-INFARCTION AND UNSTABLE ANGINA-PECTORIS [J].
AOYAMA, T ;
YUI, Y ;
MORISHITA, H ;
KAWAI, C .
CIRCULATION, 1990, 81 (06) :1784-1791
[2]  
BLERON K, 1993, WIEN KLIN WOCHENSCHR, V105, P7
[3]   EFFECTS OF NITROVASODILATORS ON PLATELET CYCLIC-NUCLEOTIDE LEVELS IN RABBIT-BLOOD - ROLE FOR CYCLIC-AMP IN SYNERGISTIC INHIBITION OF PLATELET-FUNCTION BY SIN-1 AND PROSTAGLANDIN-E1 [J].
BOWEN, R ;
HASLAM, RJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 (03) :424-433
[4]   THE ROLE OF NITRIC-OXIDE IN ENDOTHELIUM-DEPENDENT VASODILATION OF HYPERCHOLESTEROLEMIC PATIENTS [J].
CASINO, PR ;
KILCOYNE, CM ;
QUYYUMI, AA ;
HOEG, JM ;
PANZA, JA .
CIRCULATION, 1993, 88 (06) :2541-2547
[5]   CHRONIC INHIBITION OF NITRIC-OXIDE PRODUCTION ACCELERATES NEOINTIMA FORMATION AND IMPAIRS ENDOTHELIAL FUNCTION IN HYPERCHOLESTEROLEMIC RABBITS [J].
CAYATTE, AJ ;
PALACINO, JJ ;
HORTEN, K ;
COHEN, RA .
ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (05) :753-759
[6]   LOW BASAL AND STIMULATED RELEASE OF NITRIC-OXIDE IN ATHEROSCLEROTIC EPICARDIAL CORONARY-ARTERIES [J].
CHESTER, AH ;
ONEIL, GS ;
MONCADA, S ;
TADJKARIMI, S ;
YACOUB, MH .
LANCET, 1990, 336 (8720) :897-900
[7]   NITRIC-OXIDE IS A MAJOR MEDIATOR IN REACTIVE HYPEREMIA EVOKED BY A BRIEF CORONARY-OCCLUSION IN THE GUINEA-PIG HEART [J].
CHLOPICKI, S ;
GRYGLEWSKI, RJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 241 (01) :117-120
[8]   PRESERVED ENDOTHELIUM-DEPENDENT VASODILATATION IN PATIENTS WITH ESSENTIAL-HYPERTENSION [J].
COCKCROFT, JR ;
CHOWIENCZYK, PJ ;
BENJAMIN, N ;
RITTER, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (15) :1036-1040
[9]   ANTIATHEROGENIC EFFECTS OF L-ARGININE IN THE HYPERCHOLESTEROLEMIC RABBIT [J].
COOKE, JP ;
SINGER, AH ;
TSAO, P ;
ZERA, P ;
ROWAN, RA ;
BILLINGHAM, ME .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) :1168-1172
[10]   IL-1-BETA INDUCES THE COEXPRESSION OF BOTH NITRIC-OXIDE SYNTHASE AND CYCLOOXYGENASE BY ISLETS OF LANGERHANS - ACTIVATION OF CYCLOOXYGENASE BY NITRIC-OXIDE [J].
CORBETT, JA ;
KWON, G ;
TURK, J ;
MCDANIEL, ML .
BIOCHEMISTRY, 1993, 32 (50) :13767-13770